menu search

RGEN / BIIB or RGEN: Which Is the Better Value Stock Right Now?

BIIB or RGEN: Which Is the Better Value Stock Right Now?
BIIB vs. RGEN: Which Stock Is the Better Value Option? Read More
Posted: Nov 23 2022, 12:48
Author Name: Zacks Investment Research
Views: 111536

RGEN News  

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

By Zacks Investment Research
October 31, 2023

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

Repligen (RGEN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earning more_horizontal

Repligen to Report Third Quarter 2023 Financial Results

By GlobeNewsWire
October 17, 2023

Repligen to Report Third Quarter 2023 Financial Results

Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at more_horizontal

Repligen (RGEN) to Acquire Fluid Management Company Metenova

By Zacks Investment Research
September 27, 2023

Repligen (RGEN) to Acquire Fluid Management Company Metenova

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology app more_horizontal

Repligen Corporation to Present at Wells Fargo Healthcare Conference

By GlobeNewsWire
September 1, 2023

Repligen Corporation to Present at Wells Fargo Healthcare Conference

WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lea more_horizontal

Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 2, 2023

Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript

Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Inv more_horizontal

Repligen (RGEN) Q2 Earnings Surpass Estimates

By Zacks Investment Research
August 2, 2023

Repligen (RGEN) Q2 Earnings Surpass Estimates

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earning more_horizontal

Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing

By Seeking Alpha
July 18, 2023

Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 mill more_horizontal

Repligen Corporation: Not Able To Replicate The Strong Results

By Seeking Alpha
June 5, 2023

Repligen Corporation: Not Able To Replicate The Strong Results

Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic more_horizontal


Search within

Pages Search Results: